A panel of independent experts on Wednesday recommended the FDA reject an experimental ALS drug developed by the biotech BrainStorm Cell Therapeutics, marking another defeat for the long embattled ...

The race to end Bristol Myers Squibb's exclusivity on its megablockbuster cancer drug Opdivo (nivolumab) is beginning in earnest, with Amgen looking to kick off a Phase III trial next month for its ...

The Biden administration is pumping $100 million into a research project focused on combating the threat of drug-resistant bacteria, the Advanced Research Projects Agency for Health (ARPA-H) announced ...

Gritstone bio will get up to $433 million from the US government to run a Phase IIb trial early next year testing its self-amplifying mRNA vaccine candidate with an approved Covid-19 jab, the biotech ...

Boehringer Ingelheim said Wednesday that it will take part in the first round of price negotiations with the Centers for Medicare and Medicaid Services for its blockbuster type 2 diabetes drug ...

Bristol Myers Squibb is expanding its campaign for hypertrophic cardiomyopathy, or HCM, with social media-discovered singer-songwriter Sarah Cothran. The popular online influencer is speaking out as ...

The FDA is reopening the comment period on its discussion paper on using artificial intelligence in drug development, coinciding with a two-day workshop on the topic. The agency in March published ...

Bluebird bio is amending its deal with Lonza for the Swiss CDMO to boost the manufacturing capacity of bluebird's approved gene therapies Zynteglo and Skysona. The revised deal, agreed upon on Sept.

Cardiff Oncology saw its stock rise after it announced positive Phase II data from its PLK1 inhibitor onvansertib in second-line metastatic pancreatic ductal adenocarcinoma (mPDAC), spurring plans for ...

A Pfizer leukemia drug that has been approved in adults for more than a decade will soon be available for kids 1 year and older. Bosulif, also known as bosutinib, was approved by the FDA on Tuesday fo ...

Health tech unicorn Komodo Health is betting big that its latest development can disrupt how healthcare data are analyzed and put to use. Called MapLab, the tool takes data that Komodo’s aggregated ...

Roche is again pairing up with its decadelong partner Ionis Pharmaceuticals, paying $60 million upfront for the exclusive rights to two RNA assets, the companies said Wednesday morning. The deal ...